The answer is: it depends on the research goal
Together, these studies help shape safety protocols, particularly for patients with more complex CKD cases
[98], for instance, led a retrospective study of 39,275 patients with T2D on exenatide twice-daily and 381,218 patients on other glucose-lowering therapies
The entire process is transparent: no hidden membership fees, no insurance verification delays, and no surprise charges based on dose level
Over the past few years, there has been a remarkable increase in the number of users, growing from 5 million in 2020 to an estimated 40 million in 2023
Optimal macronutrient content of the diet for adolescents with prediabetes